A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Фаза 1/2 Прекращено NCT05435339

Кратко

The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity. Since this is the first study of GEN1053 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1053 dose to be tested in a larger group of participants and assess preliminary clinical activity of GEN1053. GEN1053 will be studied in a broad group of cancer patients, having different kinds of solid tumors. All participants will get GEN1053. The study consists of two parts: Part 1 tests increasing doses of GEN1053 ("escalation"), followed by Part 2 which tests the recommended phase 2 dose GEN1053 dose from Part 1 ("expansion").

Number of Participants With Dose Limiting Toxicities (DLTs)

Day 1 up to Day 21 · Participants

Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)

Up to approximately 1.5 years · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования